Tagged with Japan

Japan Experienced global leader Takafumi Horii explains the rationale behind returning to his home nation of Japan to head up Takeda’s Japan Oncology operations. Horii also touches on the significant burden of cancer in Japan, how Takeda’s solutions help meet some of the country’s most significant unmet cancer needs, as well…

Global As our thoughts here at PharmaBoardroom turn towards the summer holidays, we are happy to share the five most-read articles from our global contributor network so far in 2021. These thought leadership pieces cover topics as vital and diverse as the latest regulatory updates from China; EU-UK pharma trade; the…

Japan Writing in the July issue of DIA’s Global Forum magazine Pfizer R&D Japan’s Atsushi Kitamura examines how both pharmaceutical companies and patients in Japan can help increase patient engagement in the clinical trial process.   Patient engagement in clinical trials in Japan has been progressing steadily in the last few…

Japan While the overall Japanese pharma market is expected to remain at a similar overall value up to 2023, the oncology segment is expected to grow by five percent and by 2026, oncology is expected to represent one-fifth of the entire market. Cancer is one of the top three leading causes…

Japan Writing in the June edition of DIA’s Global Forum magazine, representatives of Japanese pharmaceutical companies with US operations outline how the COVID-19 pandemic affected their ongoing clinical studies.   The spread of COVID-19 and the resulting social activity restrictions have severely impacted drug development and threatened the continuity of clinical…

Japan “This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey,” said Christophe Weber, Takeda’s CEO, after the USD 62 billion acquisition of international biotech Shire was completed in 2019. Two years later, the Japanese giant appears to finally be on…

Japan Toshio Fujimoto, MD, MBA, the General Manager of Shonan Health Innovation Park examines why Japan – despite being well established as one of the world’s most innovative and technologically advanced countries – has lagged behind in terms of VC funding, especially in the life sciences and how this can be…

Japan The latest from Japanese pharma, including Takeda’s big profit jump, British Linepharma’s quest to get the first ever induced abortion pill for practical use, Shionogi’s promise to become the first Japanese company to get a COVID-19 vaccine approved, and the Japanese industry’s opposition to the Biden administration’s support for a…

Japan Following on from our recent compilations of 2020 new drug approvals in the USA, China, and Switzerland, see below for the Japanese PMDA’s new drug approvals list for April-October 2020. Made with Visme Infographic Maker  

Japan Japanese pharma companies are already far lower-profile than their occidental counterparts but an even lesser-known player may be Taiho Pharmaceutical, a Japanese specialty pharma player that was a pioneer in the field of oral chemotherapy, led by president Masayuki Kobayashi. The company also works in the areas of allergy and…

Japan Founded by Toyoji Naito in December 1941, in just under 80 years, Eisai has become a leading global biopharma player, with pharmaceutical revenues of USD 5.4 billion in 2019.   The company’s central philosophy of human health care (hhc) was introduced in 1992 by current director, representative corporate officer and…

Japan Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park looks at how a technology developed in Japan over a decade ago is poised to drive major medical advances and new treatments.   Here’s what we know today and what we’ll need to do tomorrow to benefit from the promises…